These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37783645)

  • 1. Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program.
    Rivers Z; Hyde B; Ronski K; Stearns D; Toll S; Ritt K; Cooney M; Nimeiri H; Federman N; Kaneva K
    Clin Ther; 2023 Nov; 45(11):1148-1150. PubMed ID: 37783645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
    Zettler ME
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial considerations for pediatric cancer drug development.
    Cooner F; Ye J; Reaman G
    J Biopharm Stat; 2023 Nov; 33(6):859-874. PubMed ID: 36749066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress.
    Charlab R; Leong R; Shord SS; Reaman GH
    Cold Spring Harb Perspect Med; 2024 Apr; 14(4):. PubMed ID: 38467448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
    Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
    J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to therapeutic drug development for childhood cancers.
    Campbell K; Ma C; DuBois SG
    Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving paradigms for new agent development in pediatric oncology.
    Flynn A; Fox E
    Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.
    Khan T; Stewart M; Blackman S; Rousseau R; Donoghue M; Cohen K; Seibel N; Fleury M; Benettaib B; Malik R; Vassal G; Reaman G
    Ther Innov Regul Sci; 2019 Mar; 53(2):270-278. PubMed ID: 29759018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and Challenges in Drug Development for Pediatric Cancers.
    Laetsch TW; DuBois SG; Bender JG; Macy ME; Moreno L
    Cancer Discov; 2021 Mar; 11(3):545-559. PubMed ID: 33277309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
    Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
    Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.
    Uguen M; Hilton M; Farid-Kapadia M; Datye A; Chohan S; Carlucci C; Dixon M; Elze M; Chen Y; Cheung KWK; Sane R; Zheng M; Choi Y
    J Biopharm Stat; 2023 Nov; 33(6):800-811. PubMed ID: 36637189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
    Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
    Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators of clinical trial enrollment in a network of community-based pediatric oncology clinics.
    Russo C; Stout L; House T; Santana VM
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28023. PubMed ID: 31556250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
    Benning TJ; Shah ND; Inselman JW; Van Houten HK; Ross JS; Wyatt KD
    Clin Trials; 2021 Dec; 18(6):732-740. PubMed ID: 34269090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative trial design in precision oncology.
    Tsimberidou AM; Müller P; Ji Y
    Semin Cancer Biol; 2022 Sep; 84():284-292. PubMed ID: 33022355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.